-transparent.png){kind=logo}
Twenty-one patients with metastatic colorectal cancer were treated with high-dose intravenous interferon alpha-2 (30-50 X 10(6) units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de-escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High-dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 X 10(6) units/m2 was greater than the maximum tolerated dose in this group of patients.
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
March 1984,
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
February 1985,
Cancer treatment reports,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
January 1994,
Investigational new drugs,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
October 1987,
Cancer treatment reports,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
August 1986,
Journal of biological response modifiers,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
February 1987,
International journal of colorectal disease,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
September 1995,
Breast cancer research and treatment,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
August 1998,
British journal of cancer,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
January 1995,
Cancer biotherapy,
R M Silgals, and
J D Ahlgren, and
J R Neefe, and
J Rothman, and
S Rudnick, and
F P Galicky, and
P S Schein
September 1996,
British journal of cancer,
